Why now

People picked up the story on June 28 after NYU Langone had already published the hospital-confirmed version, giving this a rare double window: primary medical confirmation plus mainstream human-interest reach. The story also has unusually clean emotional timing: a father, a baby, a rare metabolic disorder, a birthday surgery, and a nine-month recovery update. That makes it immediately publishable as Good News Medicine, but the breakthrough is not a new therapy. The timely angle is living-donor access and the public reminder that a transplant can turn a fatal metabolic trajectory into a survivable one when the right team, donor, and timing align.

Why now

This is not timely because organ donation is new. It is timely because a June 27 mainstream feature gives VV a weekend Good News Medicine asset with an unusually rare share hook: one person donated twice, first a kidney to a friend and later part of her liver to a 4-year-old stranger. The repeat-donor angle separates it from generic transplant stories and gives the brief a strong moral center without needing exaggerated science claims.

Why now

This is much stronger than a generic DMD update because two clocks are now running: Capricor announced five-year HOPE-2 open-label extension data for deramiocel and, separately, an FDA advisory committee meeting was scheduled for July 29 with an August 22 PDUFA target date. That gives VV a clear 'watch before the regulator decides' moment. The human frame is preservation of time in a progressive disease, but the source is company-reported and must be caveated.

Why now

The story combines a concrete first for South Carolina pediatric transplant care with a patient whose second chance is immediately legible to readers.

Why now

The update combines a powerful pediatric dosing milestone with a transition toward Phase 3, making it shareable only if the investigational boundary stays visible.